Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 27;14:955–965. doi: 10.2147/OPTH.S241044

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Horner et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Trend in median visual acuity (VA) and median central retinal thickness (CRT) for each cohort year. Both VA and CRT improved and stabilised after a loading phase of Ranibizumab. In particular, VA stabilisation at LogMAR 0.48 (Snellen 6/18) level in each year was similar as VA first achieved after the loading phase. Hence, it is possible that “vision achieved 4-weeks post-loading phase” could potentially be useful as a prognostic VA predictor in longer term.